4D Molecular Therapeutics, Inc. - FDMT STOCK NEWS

4D Molecular Therapeutics (Nasdaq: FDMT) will present initial interim 24-week data from its Phase 2 PRISM trial's Population Extension cohort on July 17, 2024, at the ASRS Annual Scientific Meeting in Stockholm. The analysis will cover 45 patients, focusing on safety and clinical activity. Additionally, a webcast will be held on the same day at 6:30 a.m. ET, featuring Dr. Arshad M. Khanani for detailed data discussion and Q&A. This study evaluates 4D-150 in treating neovascular age-related macular degeneration (AMD). A high-level safety update from PRISM and SPECTRA studies involving 139 patients will also be provided.

4D Molecular Therapeutics (Nasdaq: FDMT) presented injection-free subgroup analyses from its Phase 2 PRISM clinical trial evaluating 4D-150 in wet age-related macular degeneration (wet AMD) patients. Results showed that a single dose of 4D-150 maintained or improved visual acuity compared to the standard bimonthly aflibercept injections over 24 weeks. The treatment also resulted in a significant reduction in central subfield thickness (CST). The company plans to present interim results from the Population Extension cohort at the ASRS Annual Meeting on July 17, 2024, and will provide updates on Phase 3 trial designs later in the year.

4D Molecular Therapeutics (Nasdaq: FDMT) announced positive interim data from its Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for treating cystic fibrosis (CF) lung disease. Clinically meaningful improvements in pulmonary function (ppFEV1) were observed in 2 of 3 participants with mild to moderate baseline lung function impairment over 12 months. The treatment was well tolerated across all doses up to 1E15 vg, and widespread CFTR transgene expression was observed in lung biopsies from all participants. The 1E15 vg dose has been cleared for Phase 2 Dose Expansion, expected to begin in H2 2024, with further interim data anticipated in mid-2025.

4D Molecular Therapeutics (Nasdaq: FDMT) announced its participation at the Clinical Trials at the Summit (CTS) Meeting in Park City, Utah, on June 8, 2024. The company will present 24-week data from the Phase 2 Dose Expansion Stage of the PRISM Trial evaluating 4D-150 in wet AMD patients with severe disease activity. The presentations will cover topics including designing registration trials with the latest FDA guidance and challenges in bringing new treatment options to market. Key speakers include Robert Kim, M.D., Carl Danzig, M.D., and David Kirn, M.D.

4D Molecular Therapeutics (Nasdaq: FDMT), a leader in genetic medicines, has announced its participation in key investor conferences in June 2024. The company will be represented at the Jefferies Global Healthcare Conference on June 6 at 2:30 p.m. ET and the Goldman Sachs Global Healthcare Conference on June 11 at 2:00 p.m. ET. These events will feature fireside chats and one-on-one meetings with the management team. Archived webcasts of these presentations will be available for up to a year on the 4DMT website for interested investors.

4D Molecular Therapeutics (Nasdaq: FDMT) will present interim data from the Phase 1/2 AEROW clinical trial of aerosolized 4D-710 for cystic fibrosis lung disease at the 47th European Cystic Fibrosis Conference on June 6, 2024. Dr. Jennifer L. Taylor-Cousar will present the data at 5:00 p.m. BST. The company will also host a webcast to discuss the data and provide a program update on the same day at 8:00 a.m. ET.

The presentation, titled 'CFTR transgene expression in airway epithelial cells following aerosolized administration of the AAV-based gene therapy 4D-710 to adults with cystic fibrosis lung disease,' will be part of the session 'Where are we with new therapeutic approaches?'

The webcast will be archived on the 4DMT website for one year.

4DMT reported positive interim data from the PRISM Phase 2 Dose Expansion cohort evaluating 4D-150 in wet AMD patients, advancing into Phase 3 by Q1 2025. They presented 24-week analysis from the Population Extension cohort and Phase 1/2 AEROW trial at upcoming conferences. Additionally, they completed a public follow-on offering raising $337 million, ensuring cash runway into H1 2027.

4D Molecular Therapeutics, a leading genetic medicines company, will participate in an investor conference in May. The management team will conduct a fireside chat and be available for one-on-one meetings. The presentation will take place on May 14, 2024, at the Bank of America Health Care Conference.

4DMT, a genetic medicines company, announced presentations at the 2024 ARVO Annual Meeting, including interim results from the PRISM Phase 2 trial for 4D-150 and preclinical data on 4D-175. The Company aims to treat diseases like AMD through genetic medicine.